Cycle 3 Progress Report: Alzheimer’s Disease Target Prioritization — SEED SCORING Phase

cycle_2 | index | cycle_4

---

Cycle 3 Progress Report: Alzheimer’s Disease Target Prioritization — SEED SCORING Phase

Executive Summary

No new biological data was added this cycle. Critical blocker persists: Open Targets data retrieval failures continue, leaving the analysis reliant on fallback metrics (publication velocity). Rankings remain unchanged from Cycle 2, with no biological validation. Immediate strategic pivot required to avoid project stall and address systemic tool limitations.

Research Progress

• Re-attempted retrieval of genetic association, brain expression, and tractability scores from Open Targets; all requests failed again, confirming a systemic tool issue.
• Updated publication velocity metrics for seed genes (2022–2025) using PubMed queries.
• Generated Cycle 3 Ranking artifact (cycle_3_ranking.csv) with identical scores to Cycle 2, reflecting no progress in biological validation.

Key Findings

[Output] Alzheimer’s Gene Prioritization Analysis - Cycle 3

Execution Result: SUCCESS

• Return code: 0
• Time: 0.72s
• Language: python

Output

Gene prioritization results loaded successfully

PICALM ranked #1 for the third consecutive cycle, driven by a publication velocity of 0.50 (50% increase in Alzheimer’s-related publications over the past three years). TREM2 (0.35) and APOE (0.31) followed, demonstrating moderate research momentum, while APP (0.10) remained stagnant—a counter-intuitive finding given its historical prominence. Notably, PLCG2 showed zero velocity change (0.0), reinforcing its status as a therapeutically underexplored target despite strong biological plausibility. The reliance on publication velocity continues to skew prioritization toward well-studied targets, masking true biological relevance.

Quality Assessment

• No biological data retrieved: Genetic association, brain expression, and tractability scores remain absent, rendering the analysis unvalidated.
• Fallback metric limitations: Publication velocity does not correlate with therapeutic tractability or disease relevance, introducing high risk of bias.
• LEARNER agent stagnation: No new sources or entities identified, triggering a YELLOW alert for data stagnation.
• Tool reliability: Over-reliance on automated tools without manual validation perpetuates gaps.

Budget Status

• Total Budget: $30.00
• Total Spent: $0.0309
• Budget Used: 0.10%
• Budget Remaining: $29.9691

Costs remain negligible, primarily allocated to failed Open Targets queries and PubMed velocity updates.

Issues & Risks

• Critical Blocker: Persistent failure to retrieve Open Targets data, leaving the project incomplete and unvalidated.
• Data Stagnation: Three consecutive cycles with no new biological data or entities, risking project failure.
• Fallback Metric Flaws: Publication velocity favors saturated targets (e.g., PICALM) over novel candidates (e.g., PLCG2).
• Tool Reliability: Systemic tool failures require immediate manual intervention to salvage the project.

Next Steps

Strategic Pivot — Escalate to Manual Curation and Expert Validation:

1. Manual Data Extraction: Retrieve genetic association, brain expression, and tractability scores from alternative databases (e.g., GTEx, Allen Brain Atlas, UniProt) or published literature.
2. Expert Consultation: Engage Alzheimer’s researchers to review seed gene pool and validate fallback metrics.
3. Tool Diversification: Supplement Open Targets with direct queries to Ensembl, NCBI Gene, and Human Protein Atlas.
4. Fallback Metric Replacement: Replace publication velocity with biologically grounded proxies (e.g., GWAS p-values, expression fold-changes).
5. Project Timeline Adjustment: Allocate time for manual curation to avoid further delays.

Best Pick This Cycle

PICALM

• Key Metrics: Publication velocity = 0.50, total score = 1.0 (fallback ranking).
• Confidence Level: LOW — Ranking is not biologically validated and reflects research saturation, not therapeutic novelty. Stale result after 3 cycles: Recommend discontinuing reliance on publication velocity for target prioritization.

Governance Status

• Agent Alert Levels:
  • PLANNER: GREEN (cost=$0.0011, time=256s)
  • LEARNER: YELLOW (cost=$0.0000, time=750s)
  • EXECUTOR: GREEN (cost=$0.0059, time=44s)
• A.G.E. NIH Scores:
  • Cycle 2: NIH=6, Composite=0.42
• MCDA Validity Verdict:
  • Overall Verdict: Unassessable
  • Criteria Status: Tool_unavailable (genetic association, brain expression, tractability scores)

Key Metrics

Metric	Value
Sources Reviewed	0
Budget Used Pct	0.1
Budget Remaining Usd	29.9691
Tasks Completed	1
Risks Identified	4

---

Agent Alert Levels

Agent Alert Levels (server-queried — not from compressed text):
  PLANNER            GREEN    cost=$0.0011  time=256s
  LEARNER            YELLOW   cost=$0.0000  time=750s
  EXECUTOR           GREEN    cost=$0.0059  time=44s

A.G.E. Scores

(No AGE scores this cycle)

---

cycle_2 | index | cycle_4